154 related articles for article (PubMed ID: 29802766)
1. Engineered FcRn Binding Fusion Peptides Significantly Enhance the Half-Life of a Fab Domain in Cynomolgus Monkeys.
Datta-Mannan A; Boyles J; Huang L; Jin ZY; Peariso A; Murphy AT; Ellis B; Douglass N; Norouziyan-Cooper F; Witcher DR
Biotechnol J; 2019 Mar; 14(3):e1800007. PubMed ID: 29802766
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
[TBL] [Abstract][Full Text] [Related]
3. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
[TBL] [Abstract][Full Text] [Related]
4. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
[TBL] [Abstract][Full Text] [Related]
5. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
[TBL] [Abstract][Full Text] [Related]
6. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
7. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
[TBL] [Abstract][Full Text] [Related]
8. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
9. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
Dall'Acqua WF; Kiener PA; Wu H
J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
[TBL] [Abstract][Full Text] [Related]
10. Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn.
Ying T; Wang Y; Feng Y; Prabakaran P; Gong R; Wang L; Crowder K; Dimitrov DS
MAbs; 2015; 7(5):922-30. PubMed ID: 26179052
[TBL] [Abstract][Full Text] [Related]
11. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.
Andersen JT; Dalhus B; Viuff D; Ravn BT; Gunnarsen KS; Plumridge A; Bunting K; Antunes F; Williamson R; Athwal S; Allan E; Evans L; Bjørås M; Kjærulff S; Sleep D; Sandlie I; Cameron J
J Biol Chem; 2014 May; 289(19):13492-502. PubMed ID: 24652290
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Peptide-Fc fusion proteins.
Wu B; Sun YN
J Pharm Sci; 2014 Jan; 103(1):53-64. PubMed ID: 24285510
[TBL] [Abstract][Full Text] [Related]
14. Application of FcRn binding assays to guide mAb development.
Datta-Mannan A; Wroblewski VJ
Drug Metab Dispos; 2014 Nov; 42(11):1867-72. PubMed ID: 25024401
[TBL] [Abstract][Full Text] [Related]
15. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
16. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
[TBL] [Abstract][Full Text] [Related]
17. Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.
Datta-Mannan A; Croy JE; Schirtzinger L; Torgerson S; Breyer M; Wroblewski VJ
MAbs; 2016 Jul; 8(5):969-82. PubMed ID: 27111637
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.
Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Wroblewski VJ
J Biol Chem; 2007 Jan; 282(3):1709-17. PubMed ID: 17135257
[TBL] [Abstract][Full Text] [Related]
19. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.
Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Jiang W; Wroblewski VJ
Drug Metab Dispos; 2007 Jan; 35(1):86-94. PubMed ID: 17050651
[TBL] [Abstract][Full Text] [Related]
20. Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance.
Goulet DR; Watson MJ; Tam SH; Zwolak A; Chiu ML; Atkins WM; Nath A
Drug Metab Dispos; 2018 Dec; 46(12):1900-1907. PubMed ID: 30232177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
